Status: Not yet recruiting
Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
SAFE-HEART is a single-centre, randomized controlled trial comparing the safety and efficiency of Apixaban versus Warfarin in the early period (3 months) after repair or bioprosthetics of the mitral and aortic valve cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.
Participants needed: 120
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Meshalkin Research Institute of Pathology of CirculationUpdated: Feb 25, 2026Locations: 1
Eligibility criteria
Age ≥18 years at the time of enrolment [+3]
Mechanical valve replacement [+8]